JP2012516682A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516682A5
JP2012516682A5 JP2011547047A JP2011547047A JP2012516682A5 JP 2012516682 A5 JP2012516682 A5 JP 2012516682A5 JP 2011547047 A JP2011547047 A JP 2011547047A JP 2011547047 A JP2011547047 A JP 2011547047A JP 2012516682 A5 JP2012516682 A5 JP 2012516682A5
Authority
JP
Japan
Prior art keywords
cancer
vector according
human adenovirus
adenovirus vector
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011547047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516682A (ja
Filing date
Publication date
Priority claimed from FI20090030A external-priority patent/FI20090030A0/fi
Application filed filed Critical
Publication of JP2012516682A publication Critical patent/JP2012516682A/ja
Publication of JP2012516682A5 publication Critical patent/JP2012516682A5/ja
Pending legal-status Critical Current

Links

JP2011547047A 2009-02-02 2010-02-02 非Ad5アデノウイルスベクター並びに前記に関連する方法および使用 Pending JP2012516682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FI20090030 2009-02-02
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset
FI20095751 2009-07-02
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
PCT/IB2010/050452 WO2010086838A2 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto

Publications (2)

Publication Number Publication Date
JP2012516682A JP2012516682A (ja) 2012-07-26
JP2012516682A5 true JP2012516682A5 (enExample) 2013-03-21

Family

ID=40404558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011547047A Pending JP2012516682A (ja) 2009-02-02 2010-02-02 非Ad5アデノウイルスベクター並びに前記に関連する方法および使用

Country Status (12)

Country Link
US (1) US20120063995A1 (enExample)
EP (1) EP2391722B1 (enExample)
JP (1) JP2012516682A (enExample)
KR (1) KR20110110371A (enExample)
CN (1) CN102325887A (enExample)
AU (1) AU2010209334A1 (enExample)
BR (1) BRPI1008159A2 (enExample)
CA (1) CA2750770A1 (enExample)
FI (2) FI20090030A0 (enExample)
RU (1) RU2011136280A (enExample)
SG (1) SG173502A1 (enExample)
WO (1) WO2010086838A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006669A2 (pt) * 2010-09-24 2019-09-24 Oncos Therapeutics Oy vetores adenovirais oncolíticos e métodos e usos relacionados aos mesmos
KR20210084651A (ko) * 2013-04-18 2021-07-07 틸트 바이오세러퓨틱스 오이 향상된 입양 세포 치료
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN104946602A (zh) * 2015-06-11 2015-09-30 华中科技大学同济医学院附属同济医院 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用
EP3783032A1 (en) * 2016-09-12 2021-02-24 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
AU2018212017B2 (en) * 2017-01-30 2024-11-28 Epicentrx, Inc. Tumor selective TATA -box and CAAT-box mutants
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
US12239666B2 (en) 2018-06-19 2025-03-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1934253A (zh) * 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2012516682A5 (enExample)
JP2012513209A5 (enExample)
RU2013118723A (ru) Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
RU2011130511A (ru) Аденовирусные векторы и способы их применения, связанные с ними
RU2017134275A (ru) Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними
RU2011136280A (ru) HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
RU2013118724A (ru) Онколитические аденовирусные векторы и связанные с ними способы и применения
FI123955B (en) Oncolytic adenovirus
Addissouky et al. Can vaccines stop cancer before it starts? Assessing the promise of prophylactic immunization against high-risk preneoplastic lesions
FI3768830T3 (fi) Syöpäterapia
RU2016147003A (ru) Покрытые онколитические аденовирусы для пртивораковых вакцин
Madara et al. Evidence for an adenoma-carcinoma sequence in dimethylhydrazine-induced neoplasms of rat intestinal epithelium
CN103339262A (zh) 具有治疗作用的癌症成像:治疗诊断学
FI3768305T3 (fi) Modifioituja onkolyyttisiä adenoviruksia
JP2008508858A5 (enExample)
JP2023553773A (ja) 抗hmmw抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用
Kosaka et al. Imaging and antitumoral effect of a cyclo-oxygenase 2-specific replicative adenovirus for small metastatic gastric cancer lesions
Kim et al. In vivo bioluminescent imaging of α‐fetoprotein‐producing hepatocellular carcinoma in the diethylnitrosamine‐treated mouse using recombinant adenoviral vector
JPWO2019158914A5 (enExample)
Chehal et al. Duodenal Metastasis from Colorectal Cancer: A Case Report
Prete et al. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
Gutiu et al. Promising immunotherapeutic treatments for colon cancer
Boisgerault et al. Oncolytic virotherapy for human malignant mesothelioma: recent advances
Nadkarni et al. Hepatocellular carcinoma metastasis to the buccal mucosa masquerading as oral cavity malignancy: Case report of a rare entity
Duncan et al. Esophagogastric adenocarcinoma in an E1A/E1B transgenic model involves p53 disruption